Ion Beam (IBAB) | Stock Overview & Key Data
Ion Beam Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: €56.94 on May 8, 2017
Explore how other BE stocks compare to their 52-week ranges: View BE Market 52-Week Insights
Key Statistics
Financial Highlights
Dividend Information
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ion Beam
IBAB
|
411.94M Mid-cap | -0.25% | 11.42% | 12.66% | 35.68% | 25.00% | 38.30% | 1.44% | 0.00% | -56.09% | 275.56% | 275.56% |
|
Sequana Medical NV
SEQUA
|
40.57M Small-cap | 0.00% | 0.00% | 29.79% | 29.79% | 29.79% | 24.49% | 24.49% | 24.49% | 24.49% | 24.49% | 24.49% |
| N/A | -1.22% | 14.47% | 5.09% | 6.07% | 7.58% | 85.71% | 225.88% | 200.37% | 364.29% | 681.77% | 681.77% | |
|
UCB S.A
UCB
|
50.14B Large-cap | -0.69% | 9.37% | 1.69% | 8.86% | 10.67% | 68.19% | 220.47% | 222.73% | 332.23% | 618.13% | 618.13% |
|
Argenx SE
ARGX
|
41.43B Large-cap | -0.26% | 9.81% | 24.18% | 24.18% | 24.18% | 29.01% | 29.01% | 29.01% | 29.01% | 29.01% | 29.01% |
|
Fagron NV
FAGR
|
1.73B Large-cap | 2.31% | 0.00% | 11.19% | 17.92% | 11.95% | 13.01% | 57.64% | 25.06% | 247.12% | 93.51% | 93.51% |
Ownership & Short Interest
Calculate Your Ion Beam Investment Returns
Long-Term Investment Performance Analysis
Ion Beam stock price in Jul 2016 was €42.10, A €1,000.00 lump sum investment in Ion Beam made 9 years ago would be worth approximately €384.80 today, representing a negative return of -61.52%. This translates to an annualized return (CAGR) of -9.19%.
9 Years 10 Months Investment Scenario (Jul 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is IBAB's 52-week high and low?
- In the last 52 weeks, Ion Beam reached a high of €17.52 (on June 12, 2026) and a low of €9.90 (on N/A).
- What is the market cap and P/E ratio for IBAB?
- Curious about Ion Beam's size and valuation? Its market capitalization stands at 411.94M. When it comes to valuation, the P/E ratio (trailing twelve months) is 33.21, and the forward P/E (looking ahead) is 13.35.
- Does IBAB pay dividends? If so, what's the yield?
- Yes, Ion Beam is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 3.51%, and the company has paid an average of €0.27 per share annually over the past 3 years.
- Who are Ion Beam's main competitors or similar companies to consider before investing?
When looking at Ion Beam, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sequana Medical NV
SEQUA40.57M Healthcare Medical Devices 24.49% 24.49% Financière de Tubize
TUBN/A Healthcare Biotechnology 85.71% 225.88% UCB S.A
UCB50.14B Healthcare Biotechnology 68.19% 220.47% Argenx SE
ARGX41.43B Healthcare Biotechnology 29.01% 29.01% Fagron NV
FAGR1.73B Healthcare Drug Manufacturers - Specialty & Generic 13.01% 57.64% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Ion Beam Applications S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Ion Beam's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is N/A, the Debt to Equity ratio from the most recent quarter is 0.56, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for IBAB?
- Looking at Ion Beam's growth, its revenue over the trailing twelve months (TTM) was €620M. Compared to the same quarter last year (YoY), quarterly revenue grew by 8.10%, and quarterly earnings saw a YoY growth of -21.80%.
- How much of IBAB stock is held by insiders and institutions?
- Wondering who owns Ion Beam stock? Company insiders (like executives and directors) hold about 35.58% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 27.69%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.